NTRA · ISSUER CIK 1604821
Natera, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 7 Natera, Inc. insiders reported $0.00 of open-market purchases and $108.1M of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 29 of 29 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$108.1MInsider selling
−$108.1MNet open-market
Oct 29, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 29, 202621:35 | Oct 28, 2026from Oct 27, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $413.96 | −478 | 217,686 | -0% | −$198K | ||
| Oct 29, 202621:35 | Oct 27, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | S · Sell10b5-1 | $406.00 | −1,718 | 2,117,676 | -0% | −$698K | ||
| Oct 29, 202621:35 | Oct 28, 2026from Oct 27, 2026 | NTRA | SEC. AND CHIEF LEGAL OFFICER | S · Sell10b5-1 | $416.63 | −1,852 | 168,221 | -1% | −$772K | ||
| Oct 29, 202621:35 | Oct 28, 2026from Oct 27, 2026 | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | S · Sell10b5-1 | $416.88 | −2,172 | 104,742 | -2% | −$905K | ||
| Oct 29, 202621:35 | Oct 28, 2026from Oct 27, 2026 | NTRA | PRESIDENT, CHIEF BUS. OFFICER | S · Sell10b5-1 | $416.88 | −1,679 | 195,578 | -1% | −$700K | ||
| Oct 29, 202621:35 | Oct 28, 2026from Oct 27, 2026 | NTRA | CEO AND PRESIDENT, Director | S · Sell10b5-1 | $418.25 | −5,694 | 91,232 | -6% | −$2.4M | ||
| Oct 29, 202621:35 | Oct 28, 2026from Oct 27, 2026 | NTRA | CHIEF FINANCIAL OFFICER | S · Sell10b5-1 | $418.31 | −1,979 | 49,658 | -4% | −$828K | ||
| Oct 23, 202621:25 | Oct 21, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $410.55 | −3,150 | 218,164 | -1% | −$1.3M | ||
| Oct 20, 202621:35 | Oct 16, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $402.47 | −1,500 | 8,250 | -15% | −$604K | ||
| Oct 16, 202621:35 | Oct 15, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | S · Sell10b5-1 | $402.64 | −50,000 | 2,119,394 | -2% | −$20.1M | ||
| Oct 16, 202621:35 | Oct 15, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | M · Exercise10b5-1 | $10.41 | +50,000 | 2,169,394 | +2% | $521K | ||
| Oct 9, 202621:25 | Oct 7, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | G · Gift | — | −6,000 | 2,119,394 | -0% | — | ||
| Oct 2, 202621:35 | Oct 1, 2026 | NTRA | CEO AND PRESIDENT, Director | S · Sell10b5-1 | $413.31 | −1,273 | 96,926 | -1% | −$526K | ||
| Oct 2, 202621:35 | Oct 1, 2026 | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | S · Sell10b5-1 | $414.22 | −3,000 | 106,914 | -3% | −$1.2M | ||
| Sep 25, 202621:35 | Sep 23, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $388.01 | −18,064 | 9,000 | -67% | −$7.0M | ||
| Sep 18, 202621:35 | Sep 16, 2026 | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | G · Gift | — | −945 | 109,914 | -1% | — | ||
| Sep 17, 202621:35 | Sep 16, 2026from Sep 15, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $351.49 | −9,150 | 221,314 | -4% | −$3.2M | ||
| Sep 16, 202621:35 | Sep 15, 2026from Sep 14, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | S · Sell10b5-1 | $341.15 | −102,000 | 2,125,394 | -5% | −$34.8M | ||
| Sep 11, 202621:35 | Sep 11, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | S · Sell10b5-1 | $327.97 | −50,000 | 2,225,394 | -2% | −$16.4M | ||
| Sep 3, 202621:35 | Sep 2, 2026from Sep 1, 2026 | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | S · Sell10b5-1 | $325.88 | −18,160 | 110,859 | -14% | −$5.9M | ||
| Sep 3, 202621:05 | Sep 1, 2026 | NTRA | CEO AND PRESIDENT, Director | S · Sell10b5-1 | $320.99 | −1,698 | 98,199 | -2% | −$545K | ||
| Aug 28, 202621:35 | Aug 10, 2026 | NTRA | PRESIDENT, CHIEF BUS. OFFICER | S · Sell10b5-1Late 18d | $321.53 | −6,517 | 197,257 | -3% | −$2.1M | ||
| Aug 28, 202621:35 | Aug 6, 2026 | NTRA | PRESIDENT, CHIEF BUS. OFFICER | A · Grant10b5-1Late 22d | — | +20,000 | 203,774 | +11% | — | ||
| Aug 14, 202621:35 | Aug 10, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $325.32 | −6,000 | 230,464 | -3% | −$2.0M | ||
| Aug 7, 202621:35 | Aug 7, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | S · Sell10b5-1 | $320.90 | −2,000 | 2,000 | -50% | −$642K | ||
| Aug 7, 202621:35 | Aug 7, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $315.66 | −9,150 | 236,464 | -4% | −$2.9M | ||
| Aug 5, 202621:35 | Aug 4, 2026from Aug 3, 2026 | NTRA | CHIEF FINANCIAL OFFICER | S · Sell10b5-1 | $271.74 | −795 | 51,637 | -2% | −$216K | ||
| Aug 5, 202621:35 | Aug 3, 2026 | NTRA | CEO AND PRESIDENT, Director | S · Sell10b5-1 | $266.40 | −3,076 | 99,897 | -3% | −$819K | ||
| Aug 5, 202621:35 | Aug 3, 2026 | NTRA | PRESIDENT, CHIEF BUS. OFFICER | S · Sell10b5-1 | $267.99 | −295 | 183,774 | -0% | −$79K | ||
| Aug 5, 202621:35 | Aug 3, 2026 | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | S · Sell10b5-1 | $265.58 | −3,410 | 129,019 | -3% | −$906K | ||
| Aug 5, 202621:35 | Aug 3, 2026 | NTRA | SEC. AND CHIEF LEGAL OFFICER | S · Sell10b5-1 | $267.99 | −334 | 170,073 | -0% | −$90K | ||
| Aug 5, 202621:35 | Aug 3, 2026 | NTRA | EXECUTIVE CHAIRMAN, Director | S · Sell10b5-1 | $267.99 | −731 | 2,275,394 | -0% | −$196K | ||
| Aug 5, 202621:35 | Aug 3, 2026 | NTRA | Director, CO-FOUNDER | S · Sell10b5-1 | $267.99 | −109 | 245,614 | -0% | −$29K |